Published online Dec 12, 2014. doi: 10.5528/wjtm.v3.i3.119
Revised: September 23, 2014
Accepted: October 14, 2014
Published online: December 12, 2014
Processing time: 138 Days and 0.2 Hours
Obesity is a multifactorial disease showing a pandemic increase within the last decades in developing, and developed countries. It is associated with several severe comorbidities such as type II diabetes, hypertension, sleep apnea, non-alcoholic steatosis hepatis and cancer. Due to the increasing number of overweight individuals worldwide, research in the field of obesity has become more vital than ever. Currently, great efforts are spend to understand this complex disease from a biological, psychological and sociological angle. Further insights of obesity research come from bariatric surgery that provides new information regarding hormonal changes during weight loss. The initiation of programs for obesity treatment, both interventional and pharmaceutical, are being pursued with the fullest intensity. Currently, bariatric surgery is the most effective therapy for weight loss and resolution of comorbidities in morbid obese patients. Reasons for weight loss and remission of comorbidities following Roux-en-Y-Gastric Bypass, Sleeve Gastrectomy, and other bariatric procedures are therefore under intense investigation. In this review, however, we will focus on obesity treatment, highlighting new insights and future trends of gut hormone research, the relation of obesity and cancer development via the obesity induced chronic state of inflammation, and new potential concepts of interventional and conservative obesity treatment.
Core tip: This review focuses on the latest obesity research breakthroughs, current therapy options, future outlooks, also from a view of a surgeon as well as recently identified molecules that promote obesity and its comorbidities, outlining their great potential as new target molecules in the fight against the global pandemic, called “obesity”.